March 18, 2018 4:18 AM ET


Company Overview of AstraZeneca AB

Company Overview

AstraZeneca AB researches, develops, manufactures, and markets pharmaceuticals for gastrointestinal, cardiovascular, respiratory, and pain control. The company was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was founded in 1913 and is based in Sodertalje, Sweden. AstraZeneca AB operates as a subsidiary of AstraZeneca PLC.



Sodertalje,  151 85


Founded in 1913

24,958 Employees


46 8 55 32 60 00


46 8 55 32 90 00

Key Executives for AstraZeneca AB

Other Key
Age: 80
Head of Production
Compensation as of Fiscal Year 2017.

AstraZeneca AB Key Developments

Sosei Group Corporation Provides an Update on its Immuno-Oncology Clinical Program with AstraZeneca

Sosei Group Corporation announced that its immuno-oncology collaboration with AstraZeneca is progressing well. The first patient has been dosed in an expansion cohort in the Phase 1b segment of the Phase 1 study in advanced solid tumours. Furthermore, a new clinical study including AZD4635 to investigate novel combination therapies in EGFRm non-small cell lung cancer is expected to begin in the first quarter 2018. AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor (A2AR) antagonist discovered by Sosei subsidiary Heptares Therapeutics and licensed to AstraZeneca in 2015. AZD4635 is currently in a Phase 1 clinical trial for patients with advanced solid malignancies, the primary objective of which is to determine maximum tolerated dose (MTD) of AZD4635 alone and in combination with AstraZeneca's anti-PD-L1 antibody durvalumab. Phase 1b expansion cohorts in advanced solid tumours, are now open and the first patient has been dosed. The trial, sponsored by AstraZeneca, is expected to complete in the second half of 2019. For information on this study refer to, trial # NCT02740985. AstraZeneca, with its global biologics research and development affiliate, MedImmune, is also planning a new clinical study to assess safety, tolerability and anti-tumour activity of novel combination therapies in subjects with advanced epidermal growth factor receptor (EGFRm) mutated non-small cell lung cancer (NSCLC). This Phase 1b/2 study will evaluate the combination of MEDI9447 (an anti-CD73 antibody developed by MedImmune) with AZD4635 or TAGRISSO (osimertinib), an EGFR tyrosine kinase inhibitor for NSCLC developed by AstraZeneca.

AstraZeneca AB, Mereo BioPharma Group plc - Special Call

To consider Mereo BioPharma Group plc agreement with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an oral inhibitor of neutrophil elastase

AstraZeneca AB Presents at 5th International mRNA Health Conference, Nov-01-2017 03:20 PM

AstraZeneca AB Presents at 5th International mRNA Health Conference, Nov-01-2017 03:20 PM. Venue: Sofitel Berlin Kurfürstendamm, Augsburger Strasse 41, Berlin, Germany. Speakers: Regina Fritsche-Danielson.

Similar Private Companies By Industry

Company Name Region
Abunon AB Europe
Aditech Pharma AB Europe
Antarctic Pharma Europe
Apotek Produktion & Laboratorier AB Europe
Appetite Control Europe

Recent Private Companies Transactions

May 31, 2017
AstraZeneca AB, Neksium

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AstraZeneca AB, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at